AzTrials
AzTrials

Breast CancerNCT05201963

Erector Spinae Plane Block Versus Serratus Anterior Block on Post Mastectomy Pain Syndrome

A study testing Serratus Anterior Plane Block and Erector Spinae Plane Block in people with Breast Cancer and Post-mastectomy Pain Syndrome, run by National Cancer Institute, Egypt at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Breast cancer is the most common malignancy among females. Nearly 40-60% of breast surgery patients experience severe acute postoperative pain, with severe pain persisting for 6-12 months in almost 20-50% of patients (post mastectomy pain syndrome) which is defined according to International Association for the Study… Read more about this study

Who is it for?
Ages 18 to 65 years, women only
What is being tested?
Serratus Anterior Plane Block and Erector Spinae Plane Block
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteEgypt
Study dates
1 Nov 2021to 30 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Female patients
  • Type of surgery; Modified Radical Mastectomy MRM
  • Physical status ASA II, III.
  • Body mass index (BMI): > 20 kg/m2 and < 35 kg/m2.

Who cannot join

  • Patient refusal.
  • BMI <20 kg/m2 and >35 kg/m2
  • Known sensitivity or contraindication to drug used in the study (local anaesthetics, opioids).
  • History of psychological disorders and/or chronic pain.
  • Contraindication to regional anaesthesia e.g. local sepsis, pre- existing peripheral neuropathies and coagulopathy.
  • Severe respiratory or cardiac disorders. Advanced liver or kidney disease.
  • Pregnancy.
  • Physical status ASA IV and Male patients.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • National Cancer Institute

    Cairo, Cairo Governorate, 11796

Other trials in Egypt

About this study

Official title: Effect of Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Serratus Anterior Block on the Incidence of Post Mastectomy Pain Syndrome, Randomized Double Blinded Controlled Study

Breast cancer is the most common malignancy among females. Nearly 40-60% of breast surgery patients experience severe acute postoperative pain, with severe pain persisting for 6-12 months in almost 20-50% of patients (post mastectomy pain syndrome) which is defined according to International Association for the Study of Pain (IASP) as pain which persists more than 3 months after mastectomy/lumpectomy affecting the anterior thorax, axilla, and/or medial upper arm. Regionale anesthesia is one of the strategies with the potential to prevent the development of chronic pain following breast surgery. We hypothesize that erector spinae plane block is going to be more effective than serratus anterior plane block in the prevention of postmastectomy pain syndrome.

Read the detailed description

Background and Rationale:

Breast cancer is the most common malignancy among females with incidence of about 2.1 million women each year. It is the most common cause for cancer-related deaths among women. (1) Modified Radical Mastectomy (MRM) is one of the main surgical treatments of breast cancer. It is account for 31% of all breast surgery cases (2). Nearly 40-60% of breast surgery patients experience severe acute postoperative pain, with severe pain persisting for 6-12 months in almost 20-50% of patients (post mastectomy pain syndrome)(3-4). Pain can be severe enough to cause long-term disabilities and interfere with sleep and performance of daily activities leading to complications such as: shoulder adhesive capsulitis (frozen shoulder), complex regional pain syndrome (causalgia) and altered sensation creating an economic burden for the health care system (5-8).

The International Association for the Study of Pain (IASP) defines PMPS as pain which persists more than 3 months after mastectomy/lumpectomy affecting the anterior thorax, axilla, and/or medial upper arm.It usually describes as feeling of burning, stabbing, and pulling around the treatment side(9) The underlying pathophysiology of PMPS is highly complicated and entangle both peripheral and central sensitization. Multiple risk factors involved in the development of PMPS including Acute postoperative pain ,Age < 40 years , Increased BMI ,Diagnosis at later-stage disease , Psychosocial factors (i.e., anxiety, depression, sleep disturbances, catastrophizing) Preoperative pain and Adjuvant therapy (chemotherapy, radiation therapy(10). Like other neuropathic pain conditions, the treatment is a difficult task (11), so the focus of current research is on perioperative measures that can mitigate the modifiable risk factors for PMPS and thereby prevent patients from developing PMPS in the first place. Recognizing the importance of postoperative pain management, a number of studies have looked at strategies with the potential to prevent the development of chronic pain following breast surgery including regional anesthesia. (12)

These regional techniques include: Intercostal nerve block, Pectoral nerve Blocks (PECI \& PECS II) , Serratus Anterior Plane block (SAPB) and Erector Spinae Plane Block (ESPB). (14) Hypothesis: We hypothesize that Ultrasound guided erector spinae plane block is going to be more effective than ultrasound guided serratus anterior plane block in the prevention of postmastectomy pain syndrome in patients undergoing MRM as the injected local anesthetics acts on the dorsal and ventral rami of the thoracic spinal nerves and, thus, it is expected to block the sympathetic fibers leading to effective management of somatic and visceral pain.

Objectives:

The aim of this study is to evaluate the impact of US guided ESPB compared to US guided SAPB on the emergence of PMPS in patients undergoing MRM for cancer breast.

Study Design :

Randomized Double Blinded Controlled Study.

Population of study: 120 Female patients ASA II ,III scheduled for modified radical mastectomy under general anesthesia.

Study location: National Cancer Institute Cairo University after approval by the institutional review board.

Randomization: The patients will be randomly assigned into 3 equal comparable groups using computer generated random numbers in opaque closed envelopes, each of which will include 40 patients. Group 1 control group N=40, Group 2 ((Serratus Anterior Plane Block SAPB)) N=40.Randomization will be done by a statistician and each group of the patient will be revealed only when the included patient is transferred to the preanesthetic room.

Study Protocol: Patient assessment; History, physical exam, laboratory and radiological investigations at preoperative assessment clinic National Cancer Institute Cairo University. Preoperative assessment at night of surgery. The patients will be instructed how to report pain by means of Numeric Pain Rating Scale, in which 0 = no pain and 10 =worst possible pain. Informed consent will be obtained, base line Flanagan Quality of Life Scale (QOLS) and Barthel Activities of Daily Living scale (ADL) will be obtained.Preoperative fasting; minimum of 6 hours for food and minimum of 2 hours for water and clear fluids.20G IV cannula will be inserted. All patients will be premedicated with IV midazolam 0.01-0.02 mg\kg 30 minutes preoperatively.

Anesthetic Management:

Monitoring: all patients will be monitored continuously using ECG, NIBP, peripheral arterial oxygen saturation and end tidal carbon dioxide throughout the duration of surgery. Regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg will be used for Induction of general anaesthesia. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.

After Induction of GA group 2 patients will receive serratus anterior plane block and patients of group 3 will receive erector spinae plane block. Both blocks will be done with the patients at lateral position.

In both blocks Fujifilm Sonosite M-Turbo Ultrasound system will be used.

After performing blocks lung ultrasound is performed to exclude pneumothorax, chest is divided to 6 quadrants: Anterior upper and anterior lower quadrants Lateral upper and lower quadrants Posterior upper and lower quadrants All quadrants will be scanned especially upper quadrants looking for signs of pneumothorax such as absence of lung sliding, presence of B lines, barcode or stratosphere sign and lungpoint sign. Lung ultrasound will be done after performing block and post operative at PACU (18).

Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium o.1 m\kg will be provided every 30 minutes. Paracetamol 1000 mg and IV ketorolac 30mg will be provided as a part of multimodal analgesia. Rescue analgesia of fentanyl 1 μg/kg will be given if the mean arterial blood pressure or heart rate rises above 20% of baseline levels. Ringer acetate will be infused to replace their fluid deficit, maintenance and losses, and the patients will be mechanically ventilated at appropriate settings that keep end-tidal CO2 at 30- 35 mmHg. 1st reading of mean arterial pressure (MAP) and heart rate (HR) will be recorded before induction of general anaesthesia to be defined as a baseline reading another reading will be noted immediately before surgical incision and at 30-minute intervals intraoperatively. At the end of surgery residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes. The patients will be transferred to the post-anaesthesia care unit (PACU) where the, Numeric Pain Rating Scale score, MAP and heart rate will be noted immediately on arrival, where they will be observed for 2 hours then discharged to the ward. Lung ultrasound will be performed once again at PACU looking for signs of pneumothorax. Rescue analgesia will be provided in the form of IV morphine 3 mg boluses if the patient indicates Numeric Pain Rating Scale ≥ 4. The total amount of morphine given in 24 hours will be recorded for the 3 groups. A maximum dose of 0.5 mg/kg/24hours of morphine is allowed. Thereafter, the patients will be shifted to their respective ward, Multimodal analgesia will be provided as the following: IV paracetamol 1000mg \8 hours IV ketorolac 30mg\8 hours. There, Numeric Pain Rating Scale score, MAP and heart rate will be noted at 4, 8, 12, 16, 20 and 24 hours postoperatively. Side effects such as nausea, vomiting, sedation and respiratory depression (respiratory rate <10/minute) will be recorded. Postoperative nausea and vomiting (PONV) will be rated on a four-point verbal scale and 0.1 mg/kg of IV ondansetron will be given to patients with moderate or severe postoperative nausea and vomiting. (19) Sedation will be assessed with Ramsay score(20).

On discharge from the hospital, analgesia is going to be provided in the form of oral/parenteral paracetamol, NSAIDs and tramadol HCl according to patient preference and drugs availability for the rest of the 1st postoperative week. Average daily drug consumption after discharge will be recorded. Patients will be evaluated at the follow-up by phone call or interview at the pain clinic on 2,4,8,12 and 24 postoperative weeks. NPRS will be recorded daily in the 1st week and then at 2, 4, 8 ,12 and 24 weeks postoperttively. Neuropathic pain will be evaluated according to the Grading System for Neuropathic Pain (GSNP). Positive neuropathic cases are those with GSNP 3 (probable) or GSNP 4 (definite) i.e. GSNP ≥ 3 .(21). Flanagan Quality of Life Scale (QOLS) will be used for Quality of life assessemnt, The scale will be explained to the patients and the total score will calculated and recorded at the preoperative assessment (baseline) and at postoperative weeks 2, 3, 4, 8 ,12 and 24(22).Barthel Activities of Daily Living scale (ADL) is going to be used to record patients activity level at postoperative weeks 2, 3, 4, 8 ,12 and 24 (23).

PMPS is defined as neuropathic pain which persists more than 3 months after mastectomy/lumpectomy affecting the anterior thorax, axilla, and/or medial upper arm(9).

Patients who are going to develop post-mastectomy neuropathic pain will treated by the following regimen according to local protocol at the NCI CU: pregabalin 75-300 mg/day and amitriptyline 10-25 mg/day. Analgesics such as paracetamol, NSAIDs, tramadol HCl 100-400 mg/day and oxycodone 20-60 mg/day will be added if required according to pain severity.

Sample Size:

As there is no study addressed the same research question in these cases. Sample size was calculated according to a preliminary analysis of the first 63 patients (21 in each group) as a pilot to detect the proportion of PMPS in each group, 61% of group 1 patients developed PMPS compared to 42% and 28% in group 2 and 3 respectively. To achieve 95% confidence level a minimum sample size of 33 patients per group will be needed. To compensate for possible losses 15% will be added, 120 Patients in total will be recruited (40 per group).

Statistical analysis:

SPSS version 27.0 will be used in data analysis. Quantitative variables will be tested for normality to select appropriate statistical tests. Quantitative variables will be described as mean +- standard deviation or median and range.Comparison of of two independent groups will be done using t test or non parametric Mann Whittney u test . Data including more two groups will be tested using either by ANOVA or non parametric Kruskal-Wallis test.Post-hoc test will be used for pairwise comparisons and will be Tucky adjusted. Chi-square and Fisher Exact are going to be used for testing qualitative data . P is going to be always two tailed and set significant at 0.05 level.

Being tested
Serratus Anterior Plane Block, Erector Spinae Plane Block
Keywords
Breast Cancer, Post Mastectomy Pain Syndrome, Erector Spinae Plane Block, Serratus Anterior Plane Block
Medical subject headings
Breast Neoplasms, Acute Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Serratus Anterior Plane BlockProcedure or surgery

    Full aseptic precautions applied. Ultrasound probe will be placed on the patient's midaxillary line in the longitudinal plane (lateral position with arm abduction), at the level of 5th rib, the indicator oriented toward the operator's left. With the rib, pleural line, overlying serratus anterior and latissimus dorsi muscles visualized, then, a 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the 5th rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.6-13-MHz, linear transducer set for small parts and a depth of 1-4 cm is used for this block(15-16).

  • Erector Spinae Plane BlockProcedure or surgery

    Full aseptic precautions applied. Ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which skin, subcutaneous tissue, trapezius and erector spinae muscle will be visible superficial to T5 transverse process. Echogenic block needle will be inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1 ml normal saline . After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% will be performed. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used

Study groups in NCT05201963
Study groupRoleWhat they receive
Group 1 control groupNo interventionControl group will recive only IV Opioids
Group 2 ((Serratus Anterior Plane Block SAPB))ExperimentalPatients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 30 ml levobupivacaine 0.25%
Receives: Procedure: Serratus Anterior Plane Block
Group 3 ((Erector Spinae Plane Block ESB))ExperimentalPatients will receive Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%.
Receives: Procedure: Erector Spinae Plane Block

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of patients developing PMPS.

    Number and Percentage of patients developing PMPS

    Measured: 6 months

Secondary outcomes (13)
  1. Patient's Quality of life according to Flanagan Quality of Life Scale (QOLS)

    Flanagan Quality of Life Scale (QOLS) will be used for Quality of life assessemnt, which is a 16-item (domain) questionnaire with each item scored from 1 to 7 points. The scale will be explained to the patients and the total score will calculated and recorded at the preoperative assessment (baseline) and at postoperative weeks 2, 3, 4, 8 ,12 and 24

    Measured: 6 motnths

  2. Severity of PMPS according to Grading system for neuropathic pain (GSNP)

    Neuropathic pain will be evaluated according to the Grading System for Neuropathic Pain (GSNP). Positive neuropathic cases are those with GSNP 3 (probable) or GSNP 4 (definite) i.e. GSNP ≥ 3 . Grading system for neuropathic pain (GSNP) is as follows: Grade 1 (unlikely), Grade 2 (possible), Grade 3 (probable), and Grade 4 (definite )

    Measured: 6 motnths

  3. Postoperative Patient's activity level according to Barthel Activities of Daily Living Scale ADL

    Barthel Activities of Daily Living scale (ADL) is going to be used to record patients activity level at postoperative weeks 2, 3, 4, 8 ,12 and 24. This scale comprises 10 basic daily activities (bowel, bladder, feeding, toilet, bathing, dressing, grooming, walking, stairs and transfer) with each item scored as 0 = need complete help, 1 = need some help or 2 = need no help

    Measured: 6 months

  4. Total amount of morphine consumed postoperatively

    Total amount of morphine consumed postoperatively in mg

    Measured: 24 hours

  5. Total amount of fentanyl consumed intraoperative

    Total amount of fentanyl consumed intraoperative in mcg

    Measured: Time of surgry

  6. Change in heart rate intraoperative

    Change in heart rate intraoperative in beat\min

    Measured: 24 hours

  7. Change in Mean Artertial Blood Pressure (MAP) intraoperative

    Change in Mean Artertial Blood Pressure (MAP) intraoperative in mmHg

    Measured: 24 hours

  8. The degree of postoperative sedation according to Ramsay scores.

    Sedation will be assessed with Ramsay score (1 = anxious or restless or both; 2 = cooperative, orientated, and tranquil; 3= responding to commands; 4 = brisk response to stimulus; 5 = sluggish response to stimulus; and 6 = no response to stimulus). A Ramsay score of 5 or 6 will be considered excessively high sedation levels; a Ramsay score of 2 to 4 will be considered adequate sedation levels needing observation; a Ramsay score of 1 will be considered inadequate or insufficient sedation Levels

    Measured: 24 hours

  9. Postoperative nausea and vomiting (PONV).

    Postoperative nausea and vomiting (PONV) will be rated on a four-point verbal scale; (none =no nausea, mild =nausea but no vomiting, moderate=vomiting one attack, severe =vomiting >one attack). 0.1 mg/kg of IV ondansetron will be given to patients with moderate or severe postoperative nausea and vomiting.

    Measured: 24 hours

  10. Change in heart rate postoperatively.

    Change in heart rate postoperatively in beat\min.

    Measured: 24 hours

  11. Change in Mean Artertial Blood Pressure (MAP) postoperatively.

    Change in Mean Artertial Blood Pressure (MAP) postoperatively in mmHg.

    Measured: 24 hours

  12. Time of first rescue analgesia.

    1st time the patient asks for analgesia or 1st time when NPRS equal to or more than 10

    Measured: 24 hours

  13. Complications related to blocks

    Number of patinets developing complications related to blocks such as local anaesthetic systemic toxicity, pneumothorax and arterial puncture.

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2022
  2. Study start1 Nov 2021
  3. Primary completion30 May 2024
  4. Study completion30 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Sequential
Model description
The patients will be randomly assigned into 3 equal groups using computer generated random numbers in opaque closed envelopes, each of which will include 40 patients. Group 1 control group N=40, Group 2 ((Serratus Anterior Plane Block SAPB)) N=40 Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 30 ml levobupivacaine 0.25% and Group 3 ((Erector Spinae Plane Block ESB)) N=40 Patients will receive Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%. Randomization will be done by a statistician and each group of the patient will be revealed only when the included patient is transferred to the preanesthetic room.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
120 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05201963
Sponsor's protocol ID
AP2110-30111
Status last verified
Sep 2024
First submitted
22 Dec 2021
Last updated
1 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • De Cassai A, Bonvicini D, Correale C, Sandei L, Tulgar S, Tonetti T. Erector spinae plane block: a systematic qualitative review. Minerva Anestesiol. 2019 Mar;85(3):308-319. doi: 10.23736/S0375-9393.18.13341-4. Epub 2019 Jan 4.

    PubMed 30621377
  • Gong Y, Tan Q, Qin Q, Wei C. Prevalence of postmastectomy pain syndrome and associated risk factors: A large single-institution cohort study. Medicine (Baltimore). 2020 May;99(20):e19834. doi: 10.1097/MD.0000000000019834.

    PubMed 32443289
  • Smith WC, Bourne D, Squair J, Phillips DO, Chambers WA. A retrospective cohort study of post mastectomy pain syndrome. Pain. 1999 Oct;83(1):91-5. doi: 10.1016/s0304-3959(99)00076-7.

    PubMed 10506676
  • Miguel R, Kuhn AM, Shons AR, Dyches P, Ebert MD, Peltz ES, Nguyen K, Cox CE. The effect of sentinel node selective axillary lymphadenectomy on the incidence of postmastectomy pain syndrome. Cancer Control. 2001 Sep-Oct;8(5):427-30. doi: 10.1177/107327480100800506.

    PubMed 11579339
  • Caffo O, Amichetti M, Ferro A, Lucenti A, Valduga F, Galligioni E. Pain and quality of life after surgery for breast cancer. Breast Cancer Res Treat. 2003 Jul;80(1):39-48. doi: 10.1023/A:1024435101619.

    PubMed 12889597
  • Fecho K, Miller NR, Merritt SA, Klauber-Demore N, Hultman CS, Blau WS. Acute and persistent postoperative pain after breast surgery. Pain Med. 2009 May-Jun;10(4):708-15. doi: 10.1111/j.1526-4637.2009.00611.x. Epub 2009 Apr 22.

    PubMed 19453965
  • Capuco A, Urits I, Orhurhu V, Chun R, Shukla B, Burke M, Kaye RJ, Garcia AJ, Kaye AD, Viswanath O. A Comprehensive Review of the Diagnosis, Treatment, and Management of Postmastectomy Pain Syndrome. Curr Pain Headache Rep. 2020 Jun 11;24(8):41. doi: 10.1007/s11916-020-00876-6.

    PubMed 32529416
  • Larsson IM, Ahm Sorensen J, Bille C. The Post-mastectomy Pain Syndrome-A Systematic Review of the Treatment Modalities. Breast J. 2017 May;23(3):338-343. doi: 10.1111/tbj.12739. Epub 2017 Jan 30.

    PubMed 28133848
  • Tait RC, Zoberi K, Ferguson M, Levenhagen K, Luebbert RA, Rowland K, Salsich GB, Herndon C. Persistent Post-Mastectomy Pain: Risk Factors and Current Approaches to Treatment. J Pain. 2018 Dec;19(12):1367-1383. doi: 10.1016/j.jpain.2018.06.002. Epub 2018 Jun 30.

    PubMed 29966772
  • Blanco R. The 'pecs block': a novel technique for providing analgesia after breast surgery. Anaesthesia. 2011 Sep;66(9):847-8. doi: 10.1111/j.1365-2044.2011.06838.x. No abstract available.

    PubMed 21831090
  • Blanco R, Parras T, McDonnell JG, Prats-Galino A. Serratus plane block: a novel ultrasound-guided thoracic wall nerve block. Anaesthesia. 2013 Nov;68(11):1107-13. doi: 10.1111/anae.12344. Epub 2013 Aug 7.

    PubMed 23923989
  • Forero M, Adhikary SD, Lopez H, Tsui C, Chin KJ. The Erector Spinae Plane Block: A Novel Analgesic Technique in Thoracic Neuropathic Pain. Reg Anesth Pain Med. 2016 Sep-Oct;41(5):621-7. doi: 10.1097/AAP.0000000000000451.

    PubMed 27501016
  • Lichtenstein DA. BLUE-protocol and FALLS-protocol: two applications of lung ultrasound in the critically ill. Chest. 2015 Jun;147(6):1659-1670. doi: 10.1378/chest.14-1313.

    PubMed 26033127
  • Apfel CC, Kranke P, Eberhart LH, Roos A, Roewer N. Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth. 2002 Feb;88(2):234-40. doi: 10.1093/bja/88.2.234.

    PubMed 11883387
  • Garg R, Bhan S, Vig S. Newer regional analgesia interventions (fascial plane blocks) for breast surgeries: Review of literature. Indian J Anaesth. 2018 Apr;62(4):254-262. doi: 10.4103/ija.IJA_46_18.

    PubMed 29720750

Questions about this trial

What is this clinical trial studying?

A study testing Serratus Anterior Plane Block and Erector Spinae Plane Block in people with Breast Cancer and Post-mastectomy Pain Syndrome, run by National Cancer Institute, Egypt at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of patients developing PMPS. (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05201963, which also lists 15 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in